Scion Life Sciences

The three managing partners — Samuel Hall, Aaron Kantoff, and Tadd Wessel — lead investment decisions. All three were involved in founding the firm in 2024, and the partnership structure consolidates authority within this small group rather than dispersing it across a large investment committee.

Scion generates most of its deal flow internally by conceiving therapeutic ideas in-house and then building companies around them. The firm also sources innovations through direct academic and industry partnerships, but it primarily acts as a founder rather than a screener of externally pitched startups.

Scion operates more like a biotech company-creation studio than a conventional venture capital firm. It founds and builds companies from scratch, often starting with a therapeutic concept on paper, and stays involved through late-stage clinical development and commercialization rather than entering at a defined Series A round.

Scion invests from inception — described as 'mere ideas on napkins' — through to late-stage clinical trials and commercialization. The firm does not restrict itself to a specific stage window and will continue to fund a portfolio company across multiple rounds as long as the therapeutic program justifies further capital.

Scion states it has 'no interest in the incremental,' which implies it avoids therapies that offer only marginal improvements over existing treatments. The firm focuses on serious and life-threatening diseases where a cure or transformative clinical management change is the stated goal, ruling out development programs aimed at modest efficacy gains.

Yes. The firm actively solicits ideas from academic labs and industry partners. Its contact page invites researchers with a project to reach out, and the firm integrates externally sourced therapeutic innovations into its company-creation pipeline alongside internally conceived programs.

Adding Lalo Flores, Huw Nash, and Romesh Subramanian as venture partners broadens Scion's scientific expertise and its capacity to incubate multiple companies simultaneously. The appointments suggest the firm is scaling its founding model while keeping the core managing-partner group small.